We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Avacta Group Plc | LSE:AVCT | London | Ordinary Share | GB00BYYW9G87 | ORD 10P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 1.00 | 1.41% | 72.00 | 1,268,111 | 10:26:24 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 71.00 | 73.00 | 73.50 | 70.25 | 70.50 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 23.25M | -24.95M | -0.0695 | -10.36 | 254.92M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:29:32 | O | 1,371 | 72.245 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 18/7/2024 | 07:00 | UK RNS | Avacta Group PLC Convertible Bond Payment |
| 26/6/2024 | 19:25 | ALNC |  TRADING UPDATES: Sovereign Metals signs deal with Palladium Group |
| 26/6/2024 | 14:46 | UK RNS | Avacta Group PLC Result of AGM |
| 26/6/2024 | 07:00 | UK RNS | Avacta Group PLC AGM Business Update |
| 20/6/2024 | 07:00 | UK RNS | Avacta Group PLC Shaun Chilton appointed Non-Executive Chairman |
| 11/6/2024 | 07:00 | UK RNS | Avacta Group PLC Appointment of Nominated Adviser and Sole Broker |
| 31/5/2024 | 07:00 | UK RNS | Avacta Group PLC Posting of Annual Report and Notice of AGM |
| 23/5/2024 | 21:25 | ALNC | TRADING UPDATES: Windward wins deal; Kodal progresses at Bougouni |
| 23/5/2024 | 07:00 | UK RNS | Avacta Group PLC Successful Completion of First Cohort |
| 01/5/2024 | 11:53 | ALNC | IN BRIEF: Avacta picks Christina Coughlin to replace long-serving CEO |
Avacta (AVCT) Share Charts1 Year Avacta Chart |
|
1 Month Avacta Chart |
Intraday Avacta Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 26/7/2024 | 14:27 | Avacta – Innovative and Disruptive Technologies for Global Health Markets | 58,171 |
| 25/6/2024 | 12:57 | Covid-19. Ten Minute Test. Gamechanger!! | 19,644 |
| 23/4/2024 | 13:44 | avct The Fall!!! | 141 |
| 23/4/2023 | 22:31 | Avacta – Unique and innovative technology blipping on big pharma’s radar | 1,851 |
| 23/2/2022 | 07:14 | CV And The Deep State | 228 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2024-07-26 15:29:33 | 72.25 | 1,371 | 990.48 | O |
| 2024-07-26 15:27:44 | 72.00 | 77 | 55.44 | O |
| 2024-07-26 15:26:05 | 71.10 | 250 | 177.75 | O |
| 2024-07-26 15:25:14 | 71.08 | 20,000 | 14,216.00 | O |
| 2024-07-26 15:22:21 | 71.10 | 762 | 541.78 | O |
| Top Posts |
|---|
Posted at 26/7/2024 09:20 by Avacta Daily Update Avacta Group Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker AVCT. The last closing price for Avacta was 71p.Avacta currently has 359,042,104 shares in issue. The market capitalisation of Avacta is £258,510,315. Avacta has a price to earnings ratio (PE ratio) of -10.36. This morning AVCT shares opened at 70.50p |
Posted at 15/7/2024 09:25 by jaknife Rajraj b,”Should be an interesting week for the share price. We are due some news updates. Let’s see what happens” The only scheduled news update is the quarterly conversion that’s due under the death spiral. In order to maximise their profits from the conversion the market maker that is ultimately the owner of the death spiral needs to: A. Sell shares in the market at the highest price possible, eg by moving the price up (giving the illusion of momentum), which encourages punters to pile in and buy (from the market maker who goes short). B. Buy shares at the lowest price possible, eg by crashing the share price in the run up to the conversion date thus making the VWAP formula for the death spiral produce a low price. Who thinks that the market maker will try to maximise their profit? And hands up who thinks that the market maker is a friendly kind soul who exists to help you make a profit? JakNife |
Posted at 04/7/2024 11:51 by pwhite73 Jaknife - "The rise in the share price simply reflects the market maker moving the share price up."Perhaps but the momentum cannot take place in a vacuum. The company is clearly working hard with some success to reinvent itself but the fundamentals have not changed. That they have a peptide that can target tumours in greater amounts than standard DOX and leave healthy tissue alone is a hoax. |
Posted at 04/7/2024 11:35 by jaknife PWhite73,"The rise in the share price reflects a more credible management team and a more effective PR campaign." The rise in the share price simply reflects the market maker moving the share price up. People assume that buying activity has moved the share price up but that's not necessarily how markets work. The easiest way to encourage buying activity is to create the illusion of momentum first! There's a conversion due on the death spiral in just over two weeks time and hence the market maker needs to sell something like 5m shares between now and then. JakNife |
Posted at 03/6/2024 10:25 by pwhite73 Rajraj b - Yes I still do. AVCT has just raised £28 million. It is my opinion they are not going to waste anymore money on the never ending AVA6000 Phase 1 trials. AVCT needs to boost the share price or they can't meet their loan obligations without totally destroying what's left of shareholder value.AVCT and SOFIE are both looking at the use of FAP to kill cancer cells. AVCT as a means of recognition and SOFIE as a means of inhibition. RNS 28/03/24 - "This sub-study represents an ongoing collaboration between Avacta and SOFIE, in the use of [18F]FAPI-74 PET as a complementary diagnostic. [18F]FAPI-74 PET is currently in clinical development and for investigational use only." So we know they have been working together prior to the date of the RNS. A full joint venture to kill cancer cells will perhaps give AVCT the boost they so desperately need. |
Posted at 29/5/2024 16:10 by bones698 White utter nonsense as usual over 90% of small caps stocks will lose investors money that's why it's a complete gamble and with bad odds. Everyone thinks they have got one of the 10% that comes good but the relaity is they haven't and will lose money.More importantly is when you buy and sell any of them and getting that timing right is crucial to being able to make money in small cap companies. Loom at any number that have raised money recently at huge discounts on already depressed share prices. Most investors are down over 90% on them as you well know. That said if your buying them now you stand a good chance to make money provided they can show some good news in the coming months. The ones that tend to lose are those investing for the long term at the wrong time in the cycle, paying to high a price for hopes and dreams that are years away and need cash to get there. Avacta is such a case imo and we have already seen the share price fall massively because of this Imo there is more of the same to come and with its 120m mkt cap it looks almost certain to fall further as more cash will be required and they are so far away from any revenues or break even from the drugs in trials. I don't hold a lot of shares I post on but I am entitled to my opinion and it's usually in stark contrast to many ramping those shares. The fact I don't hold doesn't stop me having an opinion and commenting on them as those that hold them usually are biased and fail to see the downside. Again just look back here and at mnay other companies. With that in mind and the success rate being so low it's usually the negative posters which are correct and should be listened to a lot more, sadly though how many actually do or end up losing money because they don't shows how silly some investors are when the facts back this up |
Posted at 27/4/2024 15:22 by pwhite73 Down here nobody cares about conviboys, MM games, longs or shorts. This is why the thread is so quiet despite an 8% rise yesterday.What investors want to see is evidence the drug actually works. People who don't know or think they know what's going on blame the falling share price on the death spiral. I've said it before and I'll say it again AVCT does not have death spiral financing and even if it did it is not the reason why the share price has dropped from 180p in February last year to 48p today. The problem for AVCT is that the commercial pharmacology industry has seen no evidence to date that suggests AVA6000 is an improvement on Dox on its own. The data presented so far is not independent and there is no peer review in any medical journals to confirm even partial efficacy of AVA6000. As result of this AVCT cannot source the $billions of dollars normally available for early stage cancer drugs that show promising potential. This is why it had to tap the AIM mug punter market at 50p and not 500p. I have opined countless times before and will say so again AVA6000 is as bogus as the world beating LFT and it does please me that many of my earlier and later critics are beginning to see that I was right all along. |
Posted at 22/4/2024 14:09 by pwhite73 RNS 18/10/2022:-Conversion Initial Conversion Price: 25 per cent. premium to the Offer Price Reset Conversion Price: The conversion price may be reset down at the date falling 18 months after the Closing Date (as defined in Appendix III) (the "Reset Date") to the price per Ordinary Share equal to the higher of (x) the Offer Price and (y) the then current market price of the Ordinary Shares (determined by a 15-trading day volume weighted average price ("VWAP") of the Ordinary Shares prior to the day immediately preceding the Reset Date) if such price is lower than the then prevailing conversion price Reset Clawback: Following a downward reset, the Company has the right to reset the conversion price back upwards to the previous conversion price if the daily VWAP of the Ordinary Shares on each of at least 20 trading days in any period of 30 consecutive trading days is greater than 130 per cent. of the Initial Conversion Price at any time during the 9 month period following the Reset Date |
Posted at 22/4/2024 13:28 by pwhite73 JakNife - "Today's price of 42.10p was calculated using the "10% discount to VWAP" part of the death spiral pricing formula."That's only because the share price is below the conversion reference price of 88.72p Had the share price been 150p because a TR1 was released showing the European Health Care fund had taken a 20% stake there would be no 10% below VWAP conversion. Death spirals convert at a discount at any price. This arrangement does not. |
Posted at 22/4/2024 12:48 by pwhite73 JakNife - "Would anyone still like to argue that the convertible isn't a death spiral loan?"I would still like to argue the point. For the following reason. "the conversion price was reset to 88.72 pence(4), subject as provided below." Death spirals don't have a fixed conversion price. They are set at 10% or whatever below the average weighted volume over X number of days. The fact that the share price is falling is giving credence to your death spiral theory but this is an illusion. The share price is falling because of the lack of credible evidence to the claims they are making about AVA6000 not as a result of any death spiral in place. |
Posted at 29/2/2024 15:21 by pwhite73 Aman - "A reminder - convis kill companies."Wrong again. AVCT do not have a death spiral in place. The CLN was announced in October 2022 when the share price was at 119p. The share price peaked to 186p in February 2023. It dropped to 95p in July 2023 and rose to 150p in October 2023. There is no correlation between the conversions and the share price. What has gone wrong here is that the share price has failed to respond to the progress the company claims AVA6000 is making. The reasons I have given a million times. It is a mistake to blame the CLN for the decline in the share price. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
